or Try an Advanced Search...

    Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 16.62 -0.48% -0.08
    SNDX closed down 0.48 percent on Tuesday, December 3, 2024, on 58 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical SNDX trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish 0.00%
    Doji - Bearish? Reversal 0.00%
    Wide Bands Range Expansion 0.00%
    Hammer Candlestick Bullish -0.48%
    MACD Bullish Signal Line Cross Bullish -0.48%
    Wide Bands Range Expansion -0.48%
    Wide Bands Range Expansion -0.60%
    NR7 Range Contraction 0.67%
    Narrow Range Bar Range Contraction 0.67%
    Inside Day Range Contraction 0.67%
    Older End-of-Day Signals for SNDX ...

       Recent Intraday Alerts

    Alert Time
    Up 1% about 13 hours ago
    60 Minute Opening Range Breakout about 13 hours ago
    Hammer Candlestick Entry about 13 hours ago
    Rose Above Previous Day's High about 13 hours ago
    Down 1% about 14 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    SNDX Chart by TradingView
    Basic chart:

    Profile

    Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Treatment Of Breast Cancer Lung Cancer Cancer Cell Cancer Therapies Hematological Malignancies Pyridines National Cancer Institute Benzamides Histone Deacetylase Inhibitor

    Is SNDX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 27 Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
    Nov 18 Syndax secures FDA OK for new kind of leukemia drug
    Nov 18 FDA approves Syndax’s Revuforj to treat leukaemia
    Nov 15 Syndax wins FDA approval for leukemia drug revumenib
    Nov 15 Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
    Nov 14 Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
    Nov 13 Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
    Nov 13 Syndax’s revumenib meets primary results in AML trial
    Nov 12 Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
    Nov 12 Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
    See more SNDX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 25.34
    52 Week Low 15.0
    Average Volume 1,437,885
    200-Day Moving Average 20.59
    50-Day Moving Average 18.41
    20-Day Moving Average 17.55
    10-Day Moving Average 16.32
    Average True Range 0.96
    RSI (14) 42.53
    ADX 19.73
    +DI 20.92
    -DI 25.24
    Chandelier Exit (Long, 3 ATRs) 19.61
    Chandelier Exit (Short, 3 ATRs) 17.89
    Upper Bollinger Bands 21.92
    Lower Bollinger Band 13.17
    Percent B (%b) 0.39
    BandWidth 49.91
    MACD Line -0.68
    MACD Signal Line -0.72
    MACD Histogram 0.0328
    Fundamentals Value
    Market Cap 1.41 Billion
    Num Shares 84.8 Million
    EPS -2.59
    Price-to-Earnings (P/E) Ratio -6.42
    Price-to-Sales 12.67
    Price-to-Book 5.22
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 17.42
    Resistance 3 (R3) 17.46 17.24 17.29
    Resistance 2 (R2) 17.24 17.03 17.22 17.24
    Resistance 1 (R1) 16.93 16.91 17.08 16.89 17.20
    Pivot Point 16.70 16.70 16.78 16.68 16.70
    Support 1 (S1) 16.39 16.50 16.55 16.35 16.04
    Support 2 (S2) 16.17 16.37 16.15 16.00
    Support 3 (S3) 15.86 16.17 15.95
    Support 4 (S4) 15.82